NCT05995535View on ClinicalTrials.gov

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Opiate Withdrawal SyndromeOpioid Use
Interventions
DRUG

LFX/PGB

"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"

DRUG

LFX/PLA-PGB

"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"

Trial Locations (2)

19104

RECRUITING

University of Pennsylvania, Treatment Research Center, Philadelphia

21229-3618

NOT_YET_RECRUITING

Mountain Manor Treatment Center, Baltimore

All Listed Sponsors
lead

University of Pennsylvania

OTHER